Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. On our course to eradicate cancer we will develop new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.

  • Clinical trials are in progress to demonstrate the feasibility of providing prophylactic vaccines that prevent cancer.
  • Partnerships are formed to collaboratively established the viability of early cancer diagnosis.
  • FAST vaccine trials are being initiated that could dramatically reduce the time and expense of cancer treatments.

Team

STEPHEN ALBERT JOHNSTON

Founder, CEO

Stephen Albert Johnston is the inventor of the Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics),Synbody Biotechnology and HealthTell, Inc. (iCarbonX). He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.

KATHRYN SYKES, PH.D

VP Research & Product Development

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

CHRIS DIEHNELT, PH.D

Head of Operations

Chris Diehnelt has a broad interdisciplinary background that ranges from the development of mass spectrometry instrumentation, through the design and coordination of multi-investigator research projects. He developed a peptide discovery technology and led the project team that provided millions in funding, multiple patents and publications at the Center for Innovations in Medicine at the Arizona State University Biodesign Institute. He received his B.S. in Chemistry from University of North Texas, and his Ph.D. in Analytical Chemistry from Texas A&M University.

DOUG REDDING

Head of Finance

Doug Redding is an experienced financial executive with more than thirty years’ experience working with early-stage healthcare and technology companies. He spent more than twenty years as a full-time CFO then joined a small Boston-based venture capital firm as COO and general partner. Since 2007 he has advised startup companies, principally in the healthcare space, including Cleveland Clinic Innovations where he was Executive-in-Residence spinning out two highly successful new companies.

DOUGLAS THAMM DVM, PH.D.

Head of Clinical Research

Dr. Thamm is a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. He has authored over 115 peer-reviewed publications and 20 book chapters as well is editor for prominent veterinary journals.His interests include novel targeted therapies for cancer. Thamm received his degrees from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin.

EDWARD RADY

Head of Business Development

Edward Rady has broad experience in healthcare businesses, including 15 years in major Pharma, 12 years as a company founder and entrepreneur in medical education, 5 years as CEO of the largest heathcare communications company in the world, and successfully founded 3 consulting companies. Proven record of success. A quick study, skilled in creating a strategic vision, negotiating a position, simplifying and communicating complex issues. Guided by a big picture focus but a passion for the details.

Board of Directors

ANNA D. BARKER, PH.D.

Dr. Barker is co-director of Complex Adaptive Systems at Arizona State University (ASU), which serves as an organizing construct to understand and solve multidimensional problems in the biomedical sciences and biomedicine. She develops knowledge networks that leverage convergent knowledge in the biological and physical sciences, innovative teams, and novel funding approaches to better prevent and treat acute and chronic diseases. Prior to joining ASU, she was deputy director of the National Cancer Institute(NCI) where she developed and implemented strategic transdisciplinary programs designed to emphasize the synergy of large-scale and individual-initiated research to more effectively detect, prevent and treat cancer. She also served as a senior executive at Battelle Memorial Institute for 18 years and cofounded and served as CEO of a public biotechnology drug development company. She has received a number of awards for her work in support of cancer research. She completed her MA and Ph.D. degrees at The Ohio State University.

DR. GEORGE POSTE, PH.D., DVM

Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist, The Complex Adaptive Systems Initiative (CASI) at Arizona State University (ASU). Prior, he directed and built The Biodesign Institute at ASU. He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his research contributions. He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, and Haplogen GmbH. Her served the roles of Chief Science and Technology Ocer and President, R&D, at SmithKline Beecham (SB). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. He has received numerous awards and lifetime achievement recognitions.

JACQUE SOKOLOV, M.D.

Dr. Sokolov is chairman and chief executive officer of SSB Solutions, Inc., a US based and diversified healthcare management, development and financial services company. Following his formal training as an academic cardiologist, He started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation. Dr. Sokolov currently serves or has served in multiple board capacities for Public Companies including Hospira, MedCath, and PhyAmerica; Private Companies including Veterans Accountable Care Group, GlobalMed, SMG Holding Company, MyHealthDirect, NeuLife Neurological Services, LLC, IntelaTrak, PCA Holdings and SSB Solutions/HCDG; and Non Profit Organizations including Phoenix Children’s Hospital and numerous others. Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School.

Investors

CALVIRI is seeking Series A funding for infrastructure, R&D, and operations to enable multiple clinical trials in dogs and humans. We thank our current seed investors for their support.

Learn More About Investing

investors-new5

Investors

CALVIRI is seeking series A funding for infrastructure, R&D, and operations to enable multiple clinical trials in dogs and humans. We thank our current investors for their support.

  • FAST Therapeutic Vaccine
  • Early Detection
  • Responders vs. Non-Responders
  • Antibody-based
  • Highly Sensitive
  • Inexpensive & Simple
  • New Market
  • Shared Neoantigens
  • Preventative Cancer Vaccine